New Collaborations and Patents, Fresh Agreements, Positive Results, and Marketing Recommendations- Research Report on Amgen,

   New Collaborations and Patents, Fresh Agreements, Positive Results, and
   Marketing Recommendations- Research Report on Amgen, Celldex, Vivus, The
                Medicines Company, and Raptor Pharmaceuticals

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, July 15, 2013

NEW YORK, July 15, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Amgen
Inc. (NASDAQ: AMGN), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Vivus Inc.
(NASDAQ: VVUS), The Medicines Company (NASDAQ: MDCO), and Raptor
Pharmaceuticals Corp. (NASDAQ: RPTP). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Amgen Inc. Research Report

On July 9, 2013, Amgen Inc. (Amgen) announced its new collaboration agreement
with Servier, leveraging both the Companies' commitment to treat
cardiovascular disease. Amgen reported that it has obtained commercial rights
in the U.S. to Servier's novel oral drug, approved in the EU as Procoralan
(ivabradine), for chronic heart failure and stable angina in patients with
elevated heart rates, as well as an exclusive option to develop and
commercialize Servier's investigational molecule, S38844, for cardiovascular
diseases in the U.S. The Company stated that S38844 is in Phase 2 studies for
the treatment of heart failure. Sean E. Harper, M.D., Executive Vice President
of Research and Development at Amgen, said, "A critical unmet medical need
remains for patients who don't respond adequately to current available
therapies for heart failure and angina. Ivabradine, an If inhibitor, offers a
novel alternative approach for patients with elevated heart rates. We value
Servier's extensive experience in cardiovascular disease and look forward to
working with them as Amgen continues to build our presence in this area." The
Full Research Report on Amgen Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: []


Celldex Therapeutics, Inc. Research Report

On July 10, 2013, Celldex Therapeutics, Inc. (Celldex) announced that the US
Patent and Trademark Office (USPTO) has issued US Patent No: 8,481,029, 'Human
immune therapies using a CD27 agonist alone or in combination with other
immune modulators,' which broadly supports the Company's product candidate
CDX-1127, a fully human monoclonal antibody (mAb) that targets CD27 and is
currently in Phase 1 clinical development for the treatment of solid tumors
and hematologic malignancies. Celldex reported that the patent has been
assigned to the University of Southampton and that the Company has an
exclusive license to the patent based on the execution of an exclusive
licensing agreement with the University of Southampton to develop human
antibodies to CD27 in November 2008. Tibor Keler, Senior Vice President and
Chief Scientific Officer of Celldex, stated, "We continue to make excellent
progress advancing CDX-1127 and securing this key piece of intellectual
property is an important achievement as we expand our clinical program in
solid tumors and complete dose-escalation studies in hematologic
malignancies." The Full Research Report on Celldex Therapeutics, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Vivus Inc. Research Report

On July 9, 2013, Vivus Inc. (Vivus) announced that it has entered into a
License and Commercialization Agreement and a Supply Agreement with Menarini
and its wholly-owned subsidiary BERLIN-CHEMIE AG/MENARINI. The partnership
aims to commercialize and promote SPEDRA (avanafil) in over 40 European
countries, as well as Australia and New Zealand. Timothy E. Morris, Senior
Vice President of Global Corporate Development and Finance and Chief Financial
Officer of VIVUS, commented, "Menarini has tremendous know how and marketing
capabilities throughout Europe and has already established a presence in men's
health with the acquisition last year of Priligy (Dapoxetine) for treatment of
premature ejaculation (PE). The licensing process was competitive and Menarini
was chosen for their extensive presence in their territories and their history
of successful drug launches across Europe. We look forward to a long and
productive collaboration with Menarini." The Full Research Report on Vivus
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:


The Medicines Company Research Report

On July 2, 2013, The Medicines Company announced that it has achieved positive
results for its Phase 3 SOLO II clinical trial of oritavancin for the
treatment of acute bacterial skin and skin structure infections (ABSSSI)
caused by susceptible gram-positive bacteria. Clive Meanwell MD PhD, Chairman
and CEO of The Medicines Company, said, "SOLO trial data consistently show
that a single dose of oritavancin given on presentation of a patient with
ABSSSI to hospital can cure gram positive infections, including MRSA
infections, and be at least as efficacious as multiple days of twice-daily
vancomycin infusions. The safety profile also appears potentially advantageous
over vancomycin. We anticipate submitting an application for oritavancin US
market clearance in the fourth quarter of 2013 and a European filing in 2014."
The Full Research Report on The Medicines Company - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: []


Raptor Pharmaceuticals Corp. Research Report

On June 28, 2013, Raptor Pharmaceuticals Corp. (Raptor Pharmaceutical)
announced that it has received a positive opinion from the European Committee
for Medicinal Products for Human Use (CHMP), recommending marketing
authorization for PROCYSBI 25mg and 75mg gastro-resistant hard capsules,
cysteamine (as mercaptamine bitartrate) for the treatment of proven
nephropathic cystinosis. The Company said that if approved, PROCYSBI will be
indicated for the treatment of proven nephropathic cystinosis. Christopher M.
Starr, Ph.D., CEO of Raptor Pharmaceuticals, stated, "The positive opinion of
the CHMP brings us an important step closer to anticipated EU approval of
PROCYSBI subject to the European Commission review process." The Full Research
Report on Raptor Pharmaceuticals Corp. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: []



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.